EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial

Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting 11.10.2023 / 12:30 CET/CEST The issuer is solely responsible for...

Related Keywords

Ohio , United States , Cleveland , Italy , Ukraine , Russia , Milan , Lombardia , Edna Kaplan , Paula Schwartz , Jessica Breu , Robertj Fox , Daniel Vitt , Rx Communications Group , Neurological Institute , Exchange Commission , Immunic Inc , Mellen Center , Nasdaq , Distribution Services , Presents Data From Phase , Vidofludimus Calcium , Relapsing Remitting Multiple Sclerosis , Serum Neurofilament Light Chain , Both Treatment Arms , Vidofludimus Calcium Over Placebo , Progressive Multiple Sclerosis , Staff Neurologist , Multiple Sclerosis , Cleveland Clinic , Coordinating Investigator , Chief Executive Officer , Neurofilament Light Chain , Poster Number , Private Securities Litigation Reform Act , Annual Report , Investor Relations , Communications Group , Corporate News , Regulatory Announcements , Phase , Emphasis , Trial , Idofludimus , Calcium , Relapsing Remitting , Multiple , Clerosis , Smilan2023 , The , Joint , Ctrims Actrims , Meeting , Et Cest ,